GeneCentric’s leading-edge rT(I)ME Explorer Platform

The rT(I)ME Explorer Platform is translating tumor biology into robust prognostic and predictive RNA-based gene signatures. Our platform builds upon the pioneering work of co-founders Charles Perou, PhD, and Neil Hayes, MD, MPH, MS, innovators in the molecular characterization and treatment of cancer, and the immunogenomic computational pipelines developed and curated by Benjamin Vincent, MD, and Joel Parker, PhD, founders of Select ImmunoGenomics, which was acquired by GeneCentric in 2019.

Signature engine & subtypes

A keystone to drug response biomarkers and central to the rT(I)ME Explorer Platform are high-resolution molecular subtypes – inherent genomic signals within a cancer type that are characteristic of its underlying biology. Through advanced computational biology, an expanding portfolio of cancer subtypes and biomarkers accrues within the rT(I)ME Explorer Platform.

Our platform leverages enormous, publicly available gene expression datasets complemented by proprietary data and tools to develop discrete sets of key genes that define cancer subtypes and predict drug response. By reducing the multitude of genes associated with response to discrete key gene set signatures, we enable rapid development of tumor-specific clinical assays. The signatures are platform agnostic, so they are capable of being deployed on established commercial instruments.

Our ability to identify and reduce to practice a select gene set that defines cancer subtypes and predicts drug response underlies our core patents and proprietary position. Our intellectual property includes technology licensed from the University of North Carolina, based on technology developed by Drs. Perou and Hayes, as well as technology developed by GeneCentric.


EXpressCT (Expression signatures through circulating tumor signals)

TRIUMPH (Transfer Learning RNA Immune Understanding in Microenvironment PHenotype) AI